Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (currently amended) A biological reagent comprising porcine CTLA-4 ~~capable of~~ that inhibit~~ings~~ T-cell mediated rejection of a xenotransplanted organ by blocking the delivery of co-stimulatory signal 2 ~~in order~~ to prevent ~~the~~ activation of xenoreactive T-cells in ~~the~~ a recipient.

Claim 2. (withdrawn) A method for inhibiting T-cell mediated rejection of a xenotransplanted organ, comprising blocking the delivery of co-stimulatory signal 2 in order to prevent the activation of xenoreactive T-cells in the recipient.

Claim 3. (withdrawn) A method according to claim 2, comprising the administration to said recipient to a soluble form of the CTLA-4 protein from the xenogeneic donor organism.

Claim 4. (withdrawn) A method according to claim 3, wherein said soluble protein comprises the extracellular domain of porcine CTLA-4 fused to a human Cγ1 sequence.

Claim 5. (currently amended) ~~A soluble form of xenogeneic Porcine~~ An isolated protein comprising porcine CTLA-4 ~~for use as a medicament~~.

Claim 6. (currently amended) ~~A~~ The protein of claim 5 comprising the amino acid sequence of SEQ ID: 1.

Claim 7. (withdrawn) Nucleic acid which encodes the protein according to claim 6.

Claims 8-30. (canceled)

Claim 31 (new) A vector encoding the protein of claim 6.

Claim 32 (new) A cell transformed with the vector of claim 31.

Claim 33 (new) A cell that recombinantly expressed a porcine CTLA-4 protein.

Claim 34 (new) The cell of claim 33, wherein the protein comprises the amino acid sequence of SEQ ID: 1.

Claim 35 (new) The protein of claim 5 fused to an immunoglobulin.

Claim 36 (new) The protein of claim 35, wherein the immunoglobulin is a human immunoglobulin.

Claim 37 (new) The protein of claim 36, wherein the human immunoglobulin is immunoglobulin gamma (IgG).

Claim 38 (new) The protein of claim 37, wherein the immunoglobulin gamma is human Cγ1.

Claim 39 (new) The protein of claim 35, wherein a linker connects the porcine CTLA-4 to the immunoglobulin.

Claim 40 (new) The protein of claim 39, wherein the linker comprises the amino acid sequence GGSGGAA (Seq ID NO 28).

Claim 41 (new) An isolated protein comprising the extracellular domain of porcine CTLA-4.

Claim 42 (new) The isolated protein of claim 41, wherein the protein comprises the amino acid sequence of Seq ID No 19.

Claim 43 (new) The protein of claim 41 fused to an immunoglobulin.

Claim 44 (new) The protein of claim 43, wherein the immunoglobulin is a human immunoglobulin.

Claim 45 (new) The protein of claim 44, wherein the human immunoglobulin is immunoglobulin gamma (IgG).

Claim 46 (new) The protein of claim 45, wherein the immunoglobulin gamma is human Cγ1.

Claim 47 (new) The protein of claim 43, wherein a linker connects the porcine CTLA-4 to the immunoglobulin.

Claim 48 (new) The protein of claim 47, wherein the linker comprises the amino acid sequence GGSGGAA (Seq ID NO 28).

Claim 49 (new) The protein of claim 48, wherein the protein comprises the amino acid sequence of Seq ID No. 3.

Claim 50 (new) The protein of any of claims 5, 35, 41 or 43 in soluble form.

Claim 51 (new) A method for inhibiting T-cell mediated rejection of a xenotransplanted organ, comprising administering the protein of claim 5 to a recipient.

Claim 52 (new) A method for inhibiting T-cell mediated rejection of a xenotransplanted organ, comprising administering the protein of claim 50 to a recipient.